RecruitingNCT06843304

The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy


Sponsor

Chinese PLA General Hospital

Enrollment

2,000 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. By integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. Utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. The project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. Ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This large-scale Chinese observational study builds a comprehensive database of patients across the full spectrum of diabetic nephropathy — from early-stage kidney changes in people with type 2 diabetes all the way to end-stage kidney failure — to identify risk factors, biomarkers, and imaging patterns that predict how the disease progresses. Artificial intelligence will be used to analyze the combined data and develop prediction models to improve early intervention and prevent kidney failure. Adults aged 18 or older with type 2 diabetes of at least 5 years (with normal kidney function and no protein in urine), or type 2 diabetes with kidney damage who have undergone a kidney biopsy, may be eligible. Participation is observational, following patients through routine clinical visits and allowing researchers to analyze existing test results and imaging without altering their treatment. This summary was generated by AI to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06843304


Related Trials